H.C. Wainwright lowered the firm’s price target on Co-Diagnostics to $2 from $2.50 and keeps a Neutral rating on the shares following the Q1 report.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CODX:
- Co-Diagnostics reports Q1 EPS (31c) vs. (20c) last year
- Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results
- Co-Diagnostics appoints Richard Abbott as president
- Co-Diagnostics CEO Dwight Egan delivers manufacturing, commercialization update
- Co-Diagnostics Inc Welcomes Richard Abbott as New President